Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 5151-5160

  Chege, Gerald K ^a   Burgers, Wendy A ^a   Stutz, Helen ^a   Meyers, Ann E ^a   Chapman, Rosamund ^a   Kiravu, Agano ^a   Bunjun, Rubina ^a   Shephard, Enid G ^a,c   Jacobs, William R ^d   Rybicki, Edward P ^a   Williamson, Anna Lise ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL IMMUNITY; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; MYCOBACTERIUM BOVIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PRIMATE; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS LIKE AGENT;

EID: 84876330020     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03178-12     Document Type: Article

References (84)

1. UNAIDS. 2011. Global HIV/AIDS response: epidemic update and health sector progress towards universal access-progress report 2011. http: //www.unaids.org/en/media/unaids/contentassets/documents /unaidspublication/2011/20111130_UA_Report_en.pdf.
2. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, Katabira E, Bertozzi SM, Schwartlander B, Cohen MS. 2011. HIV prevention transformed: the new prevention research agenda. Lancet 378:269 -278.
3. Quiñones-Mateu ME, Vanham G. 2012. HIV microbicides: where are we now? Curr. HIV Res. 10:1-2.
4. Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD, Haynes BF, Moody MA. 2012. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol. 20:532-539.
5. Verkoczy L, Kelsoe G, Moody MA, Haynes BF. 2011. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 23:383-390.
6. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, IampietroMJ, Sanmiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89 -93.
7. McDermott AB, Koup RA. 2012. CD8(+) T cells in preventing HIV infection and disease. AIDS 26:1281-1292.
8. Burgers WA, Manrique A, Masopust D, McKinnon LR, Reynolds MR,Rolland M, Blish C, Chege GK, Curran R, Fischer W, Herrera C, Sather DN. 2012. Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res. Hum. Retroviruses 28:641- 648.
9. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
10. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
11. Schmitz JE, Johnson RP, McClure HM, Manson KH, Wyand MS, Kuroda MJ, Lifton MA, Khunkhun RS, McEvers KJ, Gillis J, Piatak M, Lifson JD, Grosschupff G, Racz P, Tenner-Racz K, Rieber EP, Kuus- Reichel K, Gelman RS, Letvin NL, Montefiori DC, Ruprecht RM, Desrosiers RC, Reimann KA. 2005. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J. Virol. 79:8131- 8141.
12. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46 -53.
13. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571.
14. Prendergast A, Goodliffe H, Clapson M, Cross R, Tudor-Williams G, Riddell A, Daniels J, Williams A, Goulder P. 2011. Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. AIDS 25:1329 -1331.
15. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, Lindqvist M, Pereyra F, Walker BD, Heckerman D, Streeck H. 2012. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J. Virol. 86: 277-283.
16. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.
17. Lu S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21:346 -351.
18. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne- Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523- 527.
19. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M, Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15: 293-299.
20. Arama C, Waseem S, Fernandez C, Assefaw-Redda Y, You L, Rodriguez A, Radosevic K, Goudsmit J, Kaufmann SH, Reece ST, Troye-Blomberg M. 2012.Arecombinant Bacille Calmette-Guerin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. Vaccine 30:5578 -5584.
21. Chapman R, Chege G, Shephard E, Stutz H, Williamson AL. 2010. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr. HIV Res. 8:282-298.
22. Dennehy M, Williamson AL. 2005. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23:1209 -1224.
23. Govan VA, Christensen ND, Berkower C, Jacobs WR, Jr, Williamson AL. 2006. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 24:2087-2093.
24. Hopkins R, Bridgeman A, Bourne C, Mbewe-Mvula A, Sadoff JC, Both GW, Joseph J, Fulkerson J, Hanke T. 2011. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur. J. Immunol. 41:3542-3552.
25. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. 2000. Recent advances with recombinant bacterial vaccine vectors. Mol. Med. Today 6:66 -71.
26. Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, Carlson KR, Buzby AP, Haynes BF, Jacobs WR, Letvin NL. 2009. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J. Virol. 83: 5505-5513.
27. Chege GK, Thomas R, Shephard EG, Meyers A, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL. 2009. A primeboost immunisation regimen using recombinant BCG and Pr55(gag) virus- like particle vaccines based on HIV type 1 subtypeCsuccessfully elicits Gag-specific responses in baboons. Vaccine 27:4857- 4866.
28. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, McShane H, Joseph J, Hanke T. 2007. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J. Virol. 81:9408 -9418.
29. Rosario M, Fulkerson J, Soneji S, Parker J, Im EJ, Borthwick N, Bridgeman A, Bourne C, Joseph J, Sadoff JC, Hanke T. 2010. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J. Virol. 84:7815-7821.
30. Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, Joseph J, Douek DC, Greenaway HY, Venturi V, Gostick E, Price DA, Both GW, Sadoff JC, Hanke T. 2010. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J. Virol. 84:5898- 5908.
31. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, Beyers N. 2007. The risk of disseminated bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25:14 -18.
32. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, Gie RP, Cotton MF, van Helden PD, Warren RM, Beyers N. 2006. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIVuninfected children. Clin. Infect. Dis. 42:548 -558.
33. Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, Gie RP, Marais BJ, van Helden P, Warren RM. 2003. Danish bacille Calmette- Guérin vaccine-induced disease in human immunodeficiency virusinfected children. Clin. Infect. Dis. 37:1226 -1233.
34. Shen Y, Zhou D, Chalifoux L, Shen L, Simon M, Zeng X, Lai X, Li Y, Sehgal P, Letvin NL, Chen ZW. 2002.Induction of an AIDS virus-related tuberculosis-like disease in macaques: a model of simian immunodeficiency virus-mycobacterium coinfection. Infect. Immun. 70:869-877.
35. Zhou D, Shen Y, Chalifoux L, Lee-Parritz D, Simon M, Sehgal PK, Zheng L, Halloran M, Chen ZW. 1999. Mycobacterium bovis bacille Calmette-Guerin enhances pathogenicity of simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis. J. Immunol. 162:2204- 2216.
36. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Jalapathy KV, Chen M, Kim J, Porcelli SA, Chan J, Morris SL, Jacobs WR. 2006. Mycobacterium tuberculosis Delta RD1 Delta panCD: a safe andlimited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24:6309-6320.
37. Sambandamurthy VK, Derrick SC, Jalapathy KV, Chen B, Russell RG, Morris SL, Jacobs WR. 2005. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun. 73: 1196-1203.
38. Sampson SL, Dascher CC, Sambandamurthy VK, Russell RG, Jacobs WR, Bloom BR, Hondalus MK. 2004. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect. Immun. 72:3031-3037.
39. Sampson SL, Mansfield KG, Carville A, Magee DM, Quitugua T, Howerth EW, Bloom BR, Hondalus MK. 2011. Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine 29: 4839-4847.
40. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. 2008. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency viruspositive persons is safer and more efficacious than BCG. Infect. Immun. 76:5200 -5214.
41. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, Morris SL, Jacobs WR, Jr. 2002. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. 8:1171-1174.
42. Burgers WA, Chege GK, Muller TL, van Harmelen JH, Khoury G, Shephard EG, Gray CM, Williamson C, Williamson AL. 2009. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J. Gen. Virol. 90:468-480.
43. Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, Davies ME, Freed DC, Hurni W, Aste-Amezaga JM, Guan L, Long R, Huang L, Harris V, Nawrocki DK, Mach H, Troutman RD, Isopi LA, Murthy KK, Rice K, Wilson KA, Volkin DB, Emini EA, Shiver JW. 2003. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:7663-7668.
44. Chege GK, Shephard EG, Meyers A, van Harmelen J, Williamson C, Lynch A, Gray CM, Rybicki EP, Williamson AL. 2008. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J. Gen. Virol. 89:2214 -2227.
45. Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, Zur MJ, Barnett SW. 2004. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 18:991-1001.
46. Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, Zur MJ, Levy JA. 2004. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine 22:2261-2272.
47. Murthy KK, Salas MT, Carey KD, Patterson JL. 2006. Baboon as a nonhuman primate model for vaccine studies. Vaccine 24:4622- 4624.
48. Williamson AL, Rybiki E, Shephard E, Gray G, Bekker LG, Downing K, Williamson C. 2012. South African HIV-1 vaccine candidates-the journey from the bench to clinical trials. S. Afr. Med. J. 102:452- 455.
49. Chapman R, Shephard E, Stutz H, Douglass N, Sambandamurthy V, Garcia I, Ryffel B, Jacobs W, Williamson AL. 2012. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8(+) T cells. PLoS One 7:e32769. doi:10.1371/journal.pone.0032769.
50. Lynch A, Meyers AE, Williamson AL, Rybicki EP. 2012. Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media. Virol. J. 9:210. doi:10.1186/1743-422X-9-210.
51. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R, Reap EA, Cilliers T, van Harmelen J, Pascual A, Ramjee G, Gray G, Johnston R, Karim SA, Swanstrom R. 2003. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res. Hum. Retroviruses 19:133-144.
52. Jaffray A, Shephard E, van Harmelen J, Williamson C, Williamson AL, Rybicki EP. 2004. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J. Gen. Virol. 85:409-413.
53. Anthony DD, Lehmann PV. 2003. T-cell epitope mapping using the ELISPOT approach. Methods 29:260 -269.
54. Chege GK, Williamson AL, Passmore JS, Bourn W, Ryffel B, Shephard EG. 2005. The immune response of the Chacma baboon to bacille Calmette Guerin: development of a primate model for BCG-based vaccine research. Vaccine 23:5783-5791.
55. Hoft DF, Leonardi C, Milligan T, Nahass GT, Kemp B, Cook S, Tennant J, Carey M. 1999. Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination. Clin. Infect. Dis. 28:785-790.
56. Kemp EB, Belshe RB, Hoft DF. 1996. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J. Infect. Dis. 174: 113-119.
57. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. 2005. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol. 79:12871-12879.
58. Yu JS, Peacock JW, Jacobs WR, Jr, Frothingham R, Letvin NL, Liao HX, Haynes BF. 2007. Recombinant Mycobacterium bovis bacillus Calmette- Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clin. Vaccine Immunol. 14:886-893.
59. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, Buonaguro FM. 2007. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25: 5968-5977.
60. Meyers A, Chakauya E, Shephard E, Tanzer FL, Maclean J, Lynch A, Williamson AL, Rybicki EP. 2008. Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol. 8:53. doi:10.1186/1472 -6750-8-53.
61. Scotti N, Alagna F, Ferraiolo E, Formisano G, Sannino L, Buonaguro L, De Stradis A, Vitale A, Monti L, Grillo S, Buonaguro FM, Cardi T. 2009. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta 229:1109 -1122.
62. Rybicki EP. 2009. Plant-produced vaccines: promise and reality. Drug Discov. Today 14:16 -24.
63. Giraldo-Vela JP, Bean AT, Rudersdorf R, Wallace LT, Loffredo JT, Erickson P, Wilson NA, Watkins DI. 2010. Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid. Immunogenetics 62:701-707.
64. Iwamoto N, Tsukamoto T, Kawada M, Takeda A, Yamamoto H, Takeuchi H, Matano T. 2010. Broadening of CD8+ cell responses in vaccinebased simian immunodeficiency virus controllers. AIDS 24:2777-2787.
65. Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, Payne R, Reddy S, Bishop K, Moodley E, Nair K, van der Stok M, McCarthy N, Rousseau CM, Addo M, Mullins JI, Brander C, Kiepiela P, Walker BD, Goulder PJ. 2007. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J. Virol. 81:3667-3672.
66. Boaz MJ, Waters A, Murad S, Easterbrook PJ, D'Sousa E, van Wheeley C, Vyakarnam A. 2003. CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects. Clin. Exp. Immunol. 134:454-463.
67. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. 2002. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 169:6376-6385.
68. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97:2709 -2714.
69. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. 2005. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. U. S. A. 102:7239 -7244.
70. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, Mccune JM, Deeks SG. 2005. Phenotypic, functional, and kinetic parameters associated with a apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 79:14169 -14178.
71. Harari A, Petitpierre S, Vallelian F, Pantaleo G. 2004. Skewed represen- tation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103:966 -972.
72. Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Bogers WMJM, ten Haaft PJF, Niphuis H, Koornstra W, Bieler K, Kostler J, Morein B, Cafaro A, Ensoli B, Wagner R, Heeney JL. 2004. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J. Virol. 78: 3333-3342.
73. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V. 2007. Superior control of HIV-1 replication by CD8+T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204:2473- 2485.
74. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781- 4789.
75. Ferrando-Martínez S, Casazza JP, Leal M, Machmach K, Munoz- Fernandez MA, Viciana P, Koup RA, Ruiz-Mateos E. 2012. Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J. Virol. 86:3667-3674.
76. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HF, Jr, Martin JN, Deeks SG, Shacklett BL. 2009. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113:3978 -3989.
77. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, Yee HF, Jr, Martin JN, Deeks SG, Shacklett BL. 2010. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J. Virol. 84:11020 -11029.
78. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, Lennox J, Amara RR. 2007. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J. Virol. 81:12071-12076.
79. Lanzavecchia A, Sallusto F. 2005. Understanding the generation and function of memory T cell subsets. Curr. Opin. Immunol. 17:326 -332.
80. Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle JH, Urrutia A, Scott-Algara D, Boufassa F, Delfraissy JF, Theze J, Venet A, Chakrabarti LA. 2007. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81:13904 -13915.
81. Burgers WA, Riou C, Mlotshwa M, Maenetje P, Rosa DD, Brenchley J, Mlisana K, Douek DC, Koup R, Roederer M, de Bruyn G, Karim SA, Williamson C, Gray CM. 2009. Association of HIV-specific and total CD8(+) T memory phenotypes in subtype C HIV-1 infection with viral set point. J. Immunol. 182:4751- 4761.
82. Brandt L, Cunha JF, Olsen AW, Chilima B, Hirsch P, Appelberg R, Andersen P. 2002. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70:672- 678.
83. Gheorghiu M, Lagranderie MR, Gicquel BM, Leclerc CD. 1994. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect. Immun. 62:4287- 4295.
84. Kameoka M, Nishino Y, Matsuo K, Ohara N, Kimura T, Yamazaki A, Yamada T, Ikuta K. 1994. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 12: 153-158.